Adenosine triphosphate-based tumor chemosensitivity assay may predict the clinical outcomes of gastric cancer patients receiving taxane-based post-operative adjuvant chemotherapy

• Published in: Chinese medical journal Vol. 135; no. 11; pp. 1383 - 1385
• Main Authors: Bian, Yicong, Huang, Minzhou, Ma, Sheng, Liu, Linsheng, Xia, Fan, Chen, Zhiyao, Yu, Di, Huang, Chenrong, Miao, Liyan
• Format: Journal Article
• Language: English
• Published: Baltimore Lippincott Williams & Wilkins 05-06-2022; Lippincott Williams & Wilkins Ovid Technologies; Wolters Kluwer
• Subjects: Adenosine triphosphate; Cancer therapies; Chemotherapy; Clinical outcomes; Correspondence; Gastric cancer; Gastrointestinal surgery; Hospitals; Metastasis; Patients; Radiation therapy
• ISSN: 0366-6999; 2542-5641
• DOI: 10.1097/CM9.0000000000002210

[4,5] Furthermore, 59 patients who received standard gastrectomy and taxane-based post-operative chemotherapy regimens were followed up to obtain overall survival (OS) and disease-free survival (DFS) data, and Kaplan–Meier analysis was used to study the correlation between the ATP-TCA results and clinical outcomes. The gastric cancer specimens were treated with five chemotherapy regimens, namely, paclitaxel (PTX) + oxaliplatin (L-OHP), docetaxel (TXT) + L-OHP, 5-fluorouracil (5-FU) + L-OHP, 5-FU + irinotecan (SN-38), and 5-FU + etoposide (VP-16), and the response was assessed using ATP-TCA method. The Kaplan–Meier curves for the 3-year survival of patients with stage III disease are shown in Supplementary Figure 1D, http://links.lww.com/CM9/B87, and significantly longer OS (P = 0.003) and DFS (P = 0.016) were observed in patients who were determined to be sensitive to taxanes by ATP-TCA. Since the survival rates of both groups were >50%, the median values for OS and DFS were not obtained in the study. [...]the response of gastric cancer to taxanes was heterogeneous, and the ATP-TCA results were well correlated with the clinical outcomes of gastric cancer patients who received taxane-based post-operative adjuvant chemotherapy. [...]this assay may aid in selecting patients who may benefit from taxane-based post-operative adjuvant chemotherapy and provide a prospective method to help with personalized medicine in addition to gene testing and biomarker detection.